

EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF NATIONAL DRUG CONTROL POLICY

2 CFR 3603 *et seq.* and 21 CFR 1400 *et seq.*

Semiannual Regulatory Agenda

AGENCY: Office of National Drug Control Policy.

ACTION: Semiannual regulatory agenda.

SUMMARY: The Regulatory Flexibility Act of 1980 and Executive Order 12866 require the semiannual issuance of an inventory of rulemaking actions under development throughout the Department, offering for public review summarized information about forthcoming regulatory actions.

FOR FURTHER INFORMATION CONTACT: For general information, please contact Robert A. Kent, General Counsel, Office of General Counsel, Office of National Drug Control Policy, Executive Office of the President, 1800 G Street NW, Washington, DC 20503 or by telephone (202) 881-8815.

SUPPLEMENTARY INFORMATION: The Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, was established by the Anti-Drug Abuse Act of 1988. The principal purpose of ONDCP is to establish policies, priorities, and objectives for the Nation's drug control program. The goals of the program are to reduce illicit drug use, manufacturing, and trafficking, drug-related crime and violence, and drug-related health consequences. To achieve these goals, the Director of ONDCP is charged with producing the National Drug Control Strategy (Strategy) to coordinate the national anti-drug efforts.

By law, the Director of ONDCP also evaluates, coordinates, and oversees both the international and domestic anti-drug efforts of Executive Branch Agencies and ensures that such efforts are consistent with the National Drug Control Strategy and sustain and complement State

and local anti-drug activities. The Director advises the President regarding changes in the organization, management, budgeting, and personnel of Federal Agencies that could affect the Nation's anti-drug efforts; and regarding Federal agency compliance with their obligations under the Strategy.

Pursuant to the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act), 21 U.S.C. 1708(c), ONDCP will propose *Criteria for Designating Emerging Drug Threats* in the United States (RIN 3201-AA02). The Agency issued an Advance Notice of Proposed Rulemaking on May 15, 2020 (85 Fed. Reg.) and solicited comments about the proposed criteria. In the future, the Agency plans to issue Guidance on the Agency website, and will forgo the execution of a Notice of Proposed Rulemaking.

NAME: Robert A. Kent,

General Counsel.